Reuters logo
BRIEF-Amicus Therapeutics presents preclinical data for Pompe program at WORLDSymposium 2017
February 15, 2017 / 1:21 PM / 8 months ago

BRIEF-Amicus Therapeutics presents preclinical data for Pompe program at WORLDSymposium 2017

Feb 15 (Reuters) - Amicus Therapeutics Inc -

* Preclinical studies showed ATB200/AT2221 reversed cellular dysfunction, increased muscle strength over 5 month period in GAA knock-out mice Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below